XORTX Therapeutics Files Q3 2024 Financial Report
Ticker: XRTX · Form: 6-K · Filed: Nov 15, 2024 · CIK: 1729214
Sentiment: neutral
Topics: financial-report, sec-filing, biotech
TL;DR
XORTX dropped its Q3 financials, check the numbers for yourself.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on November 15, 2024, reporting its financial results for the nine months ended September 30, 2024. The filing includes condensed interim consolidated financial statements and management's discussion and analysis. The company is based in Vancouver, Canada, and its CEO is Allen Davidoff.
Why It Matters
This filing provides investors with an update on XORTX Therapeutics' financial performance and operational progress for the third quarter of 2024, crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, XORTX faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Numbers
- 9 months ended September 30, 2024 — Reporting Period (Financial results for this period are detailed in the filing.)
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- November 15, 2024 (date) — Filing Date
- September 30, 2024 (date) — Reporting Period End Date
- 001-40858 (other) — SEC File Number
FAQ
What specific financial results are included in the filing for the nine months ended September 30, 2024?
The filing includes Exhibit 99.1, 'Condensed Interim Consolidated Financial Statements for the three and nine months ended September 30, 2024', and Exhibit 99.2, 'Management Discussion and Analysis for the nine months ended September 30, 2024'.
Who is the Chief Executive Officer of XORTX Therapeutics Inc. and when did they sign the report?
Allen Davidoff is the Chief Executive Officer, and the report was signed on his behalf on November 14, 2024.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the company's primary business sector?
The company is in the Pharmaceutical Preparations sector, with SIC code 2834.
What is the filing number for XORTX Therapeutics Inc. with the SEC?
The SEC file number for XORTX Therapeutics Inc. is 001-40858.
Filing Stats: 165 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2024-11-15 11:23:25
Filing Documents
- f6k_111424.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 368KB
- exh_992.htm (EX-99.2) — 242KB
- exh_993.htm (EX-99.3) — 10KB
- exh_994.htm (EX-99.4) — 10KB
- logo.jpg (GRAPHIC) — 16KB
- 0001171843-24-006401.txt ( ) — 659KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33 rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ⊠ Form 40-F □ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX THERAPEUTICS INC. (Registrant) Date: November 14, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 Condensed Interim Consolidated Financial Statements for the three and nine months ended September 30, 2024 99.2 Management Discussion and Analysis for the nine months ended September 30, 2024 99.3 CEO Certificate 99.4 CFO Certificate